Gamma Delta T-Cells

(NYB101)

Immune System

TRIAL PHASE
MECHANISMINDICATION(S)PRODUCT NAMEPreclinicalPhase 1Phase 2Phase 3
Gamma Delta T-Cells
Immuno-Oncology, Pancreatic Cancer
Nybo
(NYB101)

Immune System

Gamma Delta T-Cells
INDICATION(S):Immuno-Oncology, Pancreatic Cancer
NAME:Nybo (NYB101)
STAGE:Preclinical
Gamma Delta T-Cells

We are developing first-in-class monoclonal antibodies targeting immunosuppressive gamma delta T-cells and related mechanisms in pancreatic cancer and other solid tumors. Globally, approximately 500,000 people are diagnosed with pancreatic cancer each year, with more than 90 percent diagnosed at an advanced/metastatic stage.

With the five-year survival rate at less than seven percent, pancreatic cancer is the third leading cause of cancer death. The mainstay therapy is chemotherapy, with recently approved regimens offering minimal survival advantage of an average of less than two months. Currently, no approved targeted approaches exist and checkpoint inhibitors have not shown efficacy. 

We are developing a novel way of attacking cancer by targeting the immunosuppressive cells that to ward off the body’s natural defenses.


  • Patient Need & Market Potential
    • Globally, approximately 500,000 people are diagnosed with pancreatic cancer each year, with more than 90 percent diagnosed at an advanced/metastatic stage
    • With a five-year survival rate at less than seven percent, pancreatic cancer is the third leading cause of cancer death
    • Currently, approved immunotherapies have been generally unsuccessful in this disease setting due to a highly immunosuppressive environment that wards off the body’s natural defenses
    • Our gamma delta T-cells program aims to address this great unmet need in malignancies, particularly those with dismal prognoses that derive little benefit from current standards of care
  • Our Approach to Solving the Problem
    • Pre-clinical in vivo models validating our therapeutic concept show survival extensions in gold-standard animal models of pancreatic cancer that are superior to those previously observed in literature using approved treatments 
    • This approach is differentiated from traditional checkpoint inhibitors in immuno-oncology, yet has potential synergies with existing immunotherapies and current standards-of-care. It may also have broader applicability in the immuno-oncology space, with research underway expanding this initial work in pancreatic cancer to include other solid tumors
  • Intellectual Property
    • We currently own or have exclusive rights to a total of 25 issued patents and patent applications in 13 families or patent filings
    • One of these 13 families of IP is exclusively licensed from UCSF and covers our cognitive assessment and treatment methods related to interference processing.
  • Team
    • The team includes leading experts in immuno-oncology and pancreatic cancer
    • Key advisors include:

      Erin Adams, Ph.D., Professor at the Department of Biochemistry and Molecular Biology, and on the Committees of Immunology and Cancer Biology at the University of Chicago; Steven Leach, M.D., Director of the David M. Rubenstein Center for Pancreatic Cancer Research of Memorial Sloan-Kettering;

      George Miller, M.D., Director of S. Arthur Localio Laboratories, vice chair for research in NYU, Langone’s Department of Surgery and the leader of Perlmutter Cancer Center’s Immunology Program; and

      Diane M. Simeone, M.D., Director of the Pancreatic Cancer Center at the NYU School of Medicine and the Associate Director of Translational Research, Perlmutter Cancer Center, NYU Langone Medical Center.

    • The Gamma Delta T-Cells program team is led by Aleksandra Filipovic, M.D., Ph.D. and Eric Elenko Ph.D.
  • Milestones Achieved
    • In April 2017, we publicly disclosed the Gamma Delta T-cell program concurrent with a publication in Nature Medicine
  • Collaborations
    • The Gamma Delta T-Cells technology is exclusively licensed from the NYU School of Medicine and is based on the work of Dr. George Miller, Director of S. Arthur Localio Laboratories and Director of the Cancer Immunology Program at NYU School of Medicine. Part of the body of data supporting this approach was published recently in Nature Medicine and builds upon Dr. Miller’s work previously published in Cell
  • Expected Milestones and Timing
    • We currently expect antibodies to enter the clinic in the 2019-2020

We are developing first-in-class monoclonal antibodies aimed at neutralizing newly discovered mechanisms of immunosuppression in solid tumors. Our novel approach selectively disrupts immunosuppression to achieve a therapeutic effect on cancer.